However, targeting key DDR proteins to improve sensitization of cancer cells and circumvent cancer cell resistance remain significant challenges to achieving satisfactory therapeutic effects (Li et al., 2021; Pan et al., 2021). This evidence concerns the gene DDR1 and cancer.